INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2010

Neither Agaricus blazei nor Ganoderma lucidum mushroom supplements showed significant anticancer effects in prostate cancer patients with biochemical failure.

In an open-label study, 51 patients with biochemical failure following radical prostatectomy for non-metastasized prostate cancer took either Senseiro (Agaricus blazei Murill extract, n=32) or Rokkaku Reishi (Ganoderma lucidum, n=15) for 6 months. Forty-seven patients completed the protocol and were assessed. No partial response (a 50% or greater decrease in serum PSA) was observed in any patient. Alteration of PSA doubling time did not correlate with serum testosterone levels, and no serious adverse effects were observed.

Study type
Open-label study
Who was studied
51 Japanese patients with biochemical failure after radical prostatectomy (47 completed)
What was measured
Partial response rate (50% or more decrease in serum PSA), PSA doubling time, serum testosterone levels, and toxicity

THE PAPER

Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: an open-label study.

Yoshimura K, Kamoto T, Ogawa O, Matsui S, Tsuchiya N, Tada H, Murata K, Yoshimura K, Habuchi T, Fukushima M. Int J Urol, 2010.

PubMed 20412340 ↗DOI 10.1111/j.1442-2042.2010.02528.x ↗

CancerTop 21: Mushrooms

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.